DOI : 10.1055/s-00000054

Pharmacopsychiatry

Ausgabe 01 · Volume 38 · Januar 2005 DOI: 10.1055/s-002-3854

A joint meeting of the AGNP-TDM Group, of the Arbeitsgemeinschaft für Neuropsychopharmakologie und Pharmakopsychiatrie (AGNP) (Association of Neuropsychopharmacology and Pharmacopsychiatry) and the SGAMSP (Schweizerische Gesellschaft für Arzneimittelsicherheit in der Psychiatrie/Société suisse de pharmacovigilance en psychiatrie/Swiss Society of Pharmacovigilance in Psychiatry) in collaboration with the AMSP e.V., Germany (German Society of Pharmacovigilance in Psychiatry) and ÖAMSP (Austrian Society of Pharmacovigilance in Psychiatry)
International Meeting on Pharmacovigilance in Psychiatry, Therapeutic Drug Monitoring and Pharmacogenetics of Psychotropic Drugs
Lausanne, Switzerland, September 1–3, 2004

Pierre Baumann, Prilly-Lausanne, Switzerland, and Josef Aldenhoff, Kiel, Germany
Abstracts (HTML) Autorenliste
1
Adami, P.; König, P.; Waschgler, R.; Hausmann, A.; Waler, M.; Conca, A.: Preliminary Findings in Switching from Parenteral Haloperidol to Oral Quetiapine Treatment in the Management of Acutely Agitated Patients
2
Aderjan, R.; Herbold, M.: Forensic Analysis and Therapeutic Monitoring of Psychotropic Drugs
3
Aubry, J. M.; Baud, P.; Boucherie, M.; Leboyer, M.; Bellivier, F.; Buresi, C.; Ferrero, F.; Malafosse, A.: Antidepressant-induced Mania, Rapid Cycling and the Serotonin Transporter Gene Polymorphism
4
Bader, W.; Melchner, D.; Nonenmacher, T.; Haen, E.: Determination of Five Commonly Used Antipsychotics in Human Serum by High Performance-Liquid Chromatography (HPLC) and Electrochemical Detection
5
Bate, A.: Principles of Signal Detection and Data Mining and their Application to Psychotropic Drugs
6
Baumann, P.; Nikisch, G.; Eap, C. B.: Plasma-CSF Concentrations Relationship of Psychotropic Drugs
7
Bengtsson, F.: Motives for investing in TDM and Pharmacogenetic Tests when Treating Patients at Risk
8
Bergemann, N.; Kress, K. R.; Abu-Tair, F.; Frick, A.; Kopitz, J.: Increase in Plasma Concentrations of Amisulpride after Receiving Co-Medication with Lithium
9
Bergemann, N.; Kress, K. R.; Abu-Tair, F.; Frick, A.; Kopitz, J.: Valproate Lowers Plasma Concentrations of Olanzapine
10
Berney, P.; Dayer-Daeniker, I.; Paschoud, A.; Schulz, P.: Nefazodone Withdrawal Syndrome Responds to the Administration of Trazodone
11
Bondy, B.: Pharmacodynamic and Pharmacogenetics: Focus on Adverse Effects
12
Brøsen, K.: The Role of Pharmacogenetics/-Genomics in the Pharmacovigilance of Neuro-/Psychotropic Drugs
13
Buclin, T.; Jaquenoud Sirot, E.: Pharmacovigilance en Psychiatrie
14
Buclin, T.: Transport Proteins Regulating Drug Uptake in Brain
15
Casagrande Tango, R.; Berney, P.; Schulz, P.: What Is the Evidence for Systematic Monitoring of Tricyclic Antidepressant Concentrations?
16
Christensen, E. B.: Pharmacogenetics initiatives from an industrial Perspective
17
Czermak, C.: The Dopaminergic System, its Role in the Pathophysiology of Psychosis and Schizophrenia and Treatment by Atypical Antipsychotics
18
Dahmen, N.; Tadic, Andre; Giegling, I.; Rujescu, D.: Genetic Polymorphisms and Antipsychotic Medication: Short Term and Long Term Effects
19
Dahmen, N.; Schmidt, L. G.; Haeri, J.: Weight Gain in the AMSP System
20
Degner, D.; Niedmann, P.; Rüther, E.; Kropp, S.: Plasma Prolactin Levels During Treatment with Olanzapine
21
De Vries, C. S.: Antidepressant Utilisation and Suicide Attempts in Children and Adolescents
22
De Vries, C. S.: GP Databases, Record Linkage
23
Dragicevic, A.; Sachse, J.; Härtter, S.; Hiemke, C.; Müller, M. J.: Serum Concentrations of Quetiapine and Clinical Effects
24
Eap, C. B.; Baumann, P.: Will Genotyping and Phenotyping Methods Replace TDM in the Future?
25
Egger, C.; Stuppäck, C.: Electrolyte Disturbances Due to Dual Antidepressants
26
Eliasson, E.; Ufer, M.; Bohman, L.: Experience with CYP2D6 Genotyping in Psychiatry
27
Eschalier, A.: Pharmacovigilance in France: Recent Data on Psychotropic Drugs an Causality Assessment
28
Espnes, K. A.; Aamo, T. O.: Developing Functional Routines for TDM and Pharmacogenetic Tests in Psychiatry
29
Fattinger, K.: Epidemiology of Adverse Drug Reactions
30
Fric, M.; Härtter, S.; Finzel, M.; Distler, G.; Laux, G.; Hiemke, C.: Mirtazapine Plasma Levels: Application of a Modified Target Concentration Intervention (TCI)
31
Fric, M.; Laux, G.; Rao, M. L.; Schmidmeier, R.; Eberl, J.; Kirchmeier, T.; Betzl, F.; Brunnauer, A.: Risperidone Plasma Levels in the Elderly with Dementia
32
Gaertner, I.; Baumann, P.; Hiemke, C.; Ulrich, S.; Eckermann, G.; Gerlach, M.; Kuss, H. J.; Laux, G.; Müller-Oerlinghausen, B.; Rao, M. L.; Riederer, P.; Zernig, G.: The AGNP-TDM Expert Group Consensus Guidelines: Therapeutic Drug Monitoring in Psychiatry
33
Galatti, L.; Ettore Giustini, S.; Sessa, A.; Polimeni, G.; Salvo, F.; Spina, E.; Caputi, A. P.: Neuropsychiatric Adverse Drug Reactions in General Practice
34
Goepfert, C.; Ostermeier, C. P.; Haen, E.: Valproate-induced Encephalopathy: A Depiction of Symptoms on the Basis of a Case Report
35
Goepfert, C.; Roeder-Aigner, J.; Haen, E.: A First Report of Psychosis with Voriconazole in a Patient with AML and Bronchitis
36
Greiner, C.; Melchner, D.; Hiemke, C.; Haen, E.: Determination of Citalopram and its Main Metabolite Desmethylcitalopram in Human Serum by Column-Switching High Performance-Liquid Chromatography (HPLC) and Spectrophotometric Detection
37
Grohmann, R.; Bender, S.; Engel, R.; Rüther, E.: AMSP Methods and Results on Severe ADR due to Antipsychotics
38
Gross, A.; Joutsiniemi, S. L.; Rimon, R.; Appelberg, B.: Clozapine induced QEEG Changes Correlate with Clinical Response in Schizophrenic Patients – A Prospective, Longitudinal Study
39
Haen, E.; Rupp, M.: Relevance of Clinical Pharmacological Comments in TDM
40
Hartmann, K.: Industry Databases
41
Hendset, M.; Lunder, N.; Tanum, L.; Rudberg, I.; Refsum, H.: Individual and Dose-Dependent Variability in R- and S-Mirtazapine Ratio Among Patients Treated with Racemic Mirtazapine
42
Hiemke, C.; Kuss, H. J.; Müller, M. J.; Rao, M. L.; Dragicevic, A.; Fric, M.; Geiger, E.; Grasmäder, K.; Härtter, S.; Laux, G.; Röschke, J.; Sachse, J.; Schanz, B.; Scherer, A.: The German Network on Depression: TDM of New and Old Antidepressant Drugs
43
Holmgren, P.; Ahlner, J.: Forensic Toxicology in a Broader Perspective – With Special Reference to Psychotropic Drugs
44
Holzer, L.; Eap, C. B.; Halfon, O.; Baumann, P.: High Sedation with Low Doses of Atypical Antipsychotics in 3 Young Patients (13 to 14 Years Old)
45
Horvath, A.: AMSP Data on Antidepressants and Suicidality
46
Ignjatovic, D.; Ignjatovic, M.; Nutt, D. J.: Pharmacological Treatment of Late-Life Depression
47
Ignjatovièová, D.; Ignjatovic, M.: Comparison of Galantamine and Rivastigmin Effects –12-Month Study
48
Jaquenoud Sirot, E.; Stephan, P.; Knezevic, B.; Eap, C. B.; Baumann, P.: TDM and Pharmacogenetic Tests as Tools in Pharmacovigilance: Case Reports
49
Jaquenoud Sirot, E.; Eap, C. B.; Baumann, P.: Follow-Up of a Pharmacovigilance Study in Psychiatry Involving TDM and Pharmacogenetic Testing
50
Jaquenoud Sirot, E.; Stephan, P. L.; Baumann, P.: Severe Bruising as an Adverse Event: Chocolate or Fluvoxamine? Case Report
51
Kirchheiner, J.: Genotype Specific Dosages of Antidepressants – A Proposal
52
Kirchherr, H.; Kühn-Velten, W. N.: A Simple and Sensitive Method for the Determination of Tranylcypromine in Plasma with LC-MS/MS
53
Konstantinidis, A.; Grohmann, R.; Horvath, A.; Kasper, S.: Psychotropic Drug Use in Psychiatric Inpatients: Recent Trends in Dosage and Choice of Psychotropic Drug in 3 German Speaking Countries
54
Kropp, S.: Galactorrhea and Antipsychotic Use: Data from the AMSP
55
Kuss, H. J.; Ackenheil, M.: No Change of Amitriptyline Concentration by Comedication of Tranylcypromine
56
Kuss, H. J.: Analytical Issues Regarding Psychotropic Agents and Weighted Regression for Data Interpretation
57
Laux, G.: Workshop: Psychotropic Drugs and Driver Impairment
58
Maier, W.; Höfgen, B.; Wagner, M.; Rietschel, M.; Groß, M.; von Widdern, O.; Zobel, A.: Genetic Analysis of Neurobiological Indicators of Antidepressant Drug Response
59
Mancama, D.; Kerwin, R. W.; Arranz, M. J.: Genetics and the Pharmacokinetics and Pharmacodynamics of Psychiatric Drugs
60
Mann, K.; Bisdas, S.; Danielowski, K.; Hiemke, C.: Therapeutic Drug Monitoring of Antidepressants and Length of Stay of Psychiatric Inpatients
61
Moore, N.: Examples of Use of Psychopharmacoepidemiology
62
Moore, N.: General Introduction ISOP
63
Nesvåg, R.; Tanum, L.: Therapeutic Drug Monitoring of Patients on Risperidone Depot
64
Nikisch, G.; Mathé, A. A.; Baumann, P.: Clinical Relevance of Citalopram (CIT) Plasma and Cerebrospinal Fluid (CSF) Concentrations: Impact with CSF Monoamine Metabolites
65
Paus, E.; Lepore, M.; Jonzier-Perey, M.; Rochat, B.; Hornung, J. P.; Baumann, P.: Metabolism of Citalopram by MAO: Pharmacogenetic and Kinetic Animal Studies
66
Pfuhlmann, B.; Unterecker, S.; Polak, T.; Burger, R.; Riederer, P.: Therapeutic Drug Monitoring in a Naturalistic Clinical Setting
67
Prapotnik, M.; König, P.: Rare Combinations of Ssris in Cotherapy with Other Antidepressants: The Importance of TDM
68
Refsum, H.; Hendset, M.; Rudberg, I.: Therapeutic Drug Monitoring in Psychiatry: Experience from Norway
69
Reis, M.; Prochazka, J.; Bengtsson, F.: Pharmacokinetic Variance of Mirtazapine and N-Demethylmirtazapine in Patients Treated for Major Depressive Disorder: A Six Months Therapeutic Drug Monitoring Study
70
Renger, H.: Dopamine-Mediated Adverse Drug Reactions Caused by Atypical Antipsychotics
71
Rentsch, K.: LC-MS(/MS) Analysis of Psychotropic Drugs
72
Rexelius, M.; Cherma, M.; Bengtsson, F.: Ziprasidone and Methyldihydroziprasidone Kinetics as Displayed in the Naturalistic Clinical Setting by Applying a TDM-Routine
73
Rieger-Gies, A.; Heller, S.; Stroba, G.; Daum-Kreysch, E.; Sachse, J.; Härtter, S.; Hiemke, C.: Storage and Transport Stability of New Antidepressant and Antipsychotic Drugs
74
Rosenqvist, U.; Albertsen, U.; Bengtsson, F.: Therapeutic Drug Monitoring of Paroxetine in a Naturalistic Clinical Setting
75
Rothenhöfer, S.; Mehler-Wex, C.; Schupp, U.; Wewetzer, C.; Gerlach, M.: Therapeutic Drug Monitoring of Quetiapine in Child and Adolescents
76
Rygula, R.; Hiemke, C.; Abumaria, N.; Fluegge, G.; Ruether, E.; Havemann-Reinecke, U.: Pharmacokinetic and Behavioural Effects of Antidepressants Given Orally via Drinking Water in Rats
77
Sachse, J.; Christians, U.; Hiemke, C.: Automated Analysis of Antipsychotic Drugs Using Liquid Chromatography with Column Switching
78
Schuhmann, T.: Sibutramin-induced Hypomania – A Case Report
79
Schuhmann, T.: Lewy Body Dementia, Pharmacotherapeutic Security and Differential Indication of Antipsychotics According to Adverse Effects – A Case Report
80
Schwarz, M. J.; Spellmann, I.; Müller-Arends, A.; Strassnig, M.; Zach, J.; Weber, K.; Müller, N.; Möller, H. J.; Riedel, M.: Risperidone Plasma Levels, Clinical Response and Side-Effects
81
Shams, M.; Arneth, B.; Lackner, K.; Hiemke, C.; Haertter, S.: Rapid and Reliable Genotyping Procedure for Detection of Alleles with Mutation, Deletion or/and Duplication of the CYP2D6-Gene
82
Sjöqvist, F.: TDM and Pharmacogenetics of Tricyclic Antidepressants – The Original Ideas
83
Sjöqvist, F.: CYP2D6– a Key Enzyme in the Metabolism of Antidepressants and Neuroleptics
84
Spigset, O.: Treatment of Women in Pregnancy and Lactation with Psychotropic Drugs
85
Spina, E.; Scordo, M. G.: TDM and Pharmacogenetics in Relation to Side Effect Monitoring in Psychiatry
86
Stübner, S.; Grohmann, R.; Engel, R.; Möller, H. J.; Hippius, H.; Rüther, E.: „Atypical Dyskinesia“ – Uncommon Adverse Reactions due to Psychotropic Drugs
87
Tauscher, J.: Brain Receptor Occupancy: A Measure for Pharmacological Activity?
88
Aamo, T.: Developing Functional Routines for TDM and Pharmacogenetics Tests in Psychiatry
89
Ulrich, S.; Pawelzik, M.; Göhring, J.: Pharmacovigilance of Jatrosom N (Tranylcypromine): Preliminary Data of a Post-Authorisation Surveillance Study
90
Ulrich, S.; Sandmann, U.; Genz, A.: Haloperidol Pyridinium Serum Levels and Tardive Dyskinesia
91
Van der Velden, J. W.: The international Society for Pharmacoepidemiology
92
Van der Velden, J. W.: Current Issues and Legislation in Pharmacovigilance
93
Van Grootheest, K.: National Databases
94
Woggon, B.: High Dose Treatment of Patients Suffering from Mood Disorders
95
Zernig, G.; Lechner, T.; Kramer-Reinstadler, K.; Hinterhuber, H.; Hiemke, C.; Saria, A.: The Practice of TDM in an Austrian University Hospital Setting: What the Clinician Still has to be Reminded of ...